In a phase II trial in patients with BRAF V600-mutant melanoma who had previously progressed on BRAF inhibitors (with or without MEK inhibitors) and were off-treatment for at least 12 weeks, dabrafenib plus trametinib rechallenge resulted in antitumor activity. Here, MAP2K7 is linked to melanoma.